Choline kinase alpha depletion selectively kills tumoral cells

Current Cancer Drug Targets

Volumn 8, Issue 8, 2008, Pages 709-719

  Bañez Coronel, Mónica ^a   Ramírez De Molina, Ana ^a   Rodríguez González, Agustín ^a   Sarmentero, Jacinto ^a   Ramos, Ma Angeles ^a   García Cabezas, Miguel Ángel ^a   García Oroz, Lourdes ^a   Lacal, Juan Carlos ^a,b  

^a CSIC   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Anticancer drugs; Apoptosis; ChoK inhibitors; Choline kinase; shRNA; Target validation

Indexed keywords

CHOLINE KINASE; CHOLINE KINASE ALPHA; DOXYCYCLINE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HEK293; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RNA INTERFERENCE; TUMOR XENOGRAFT; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CHOLINE KINASE; DNA PRIMERS; FLOW CYTOMETRY; GENE SILENCING; HUMANS; MICROSCOPY, FLUORESCENCE; RNA; RNA INTERFERENCE;

EID: 57449119711     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786733432     Document Type: Article

References (39)

1. Aoyama, C.; Liao, H.; Ishidate, K. Structure and function of choline kinase isoforms in mammalian cells. Prog. Lipid Res. 2004, 43, 266-281.
2. Cuadrado, A.; Carnero, A.; Dolfi, F.; Jimenez, B.; Lacal, J. C. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993, 8, 2959-2968.
3. Ramirez de Molina, A.; Banez-Coronel, M.; Gutierrez, R.; Rodriguez-Gonzalez, A.; Olmeda, D.; Megias, D.; Lacal, J. C. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004, 64, 6732-6739.
4. Jimenez, B.; del Peso, L.; Montaner, S.; Esteve, P.; Lacal, J. C. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J. Cell. Biochem. 1995, 57, 141-149.
5. Rodriguez-Gonzalez, A.; Ramirez de Molina, A.; Fernandez, F.; Lacal, J. C. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004, 23, 8247-8259.
6. Hernandez-Alcoceba, R.; Saniger, L.; Campos, J.; Nunez, M. C.; Khaless, F.; Gallo, M. A.; Espinosa, A.; Lacal, J. C. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997, 15, 2289-2301.
7. Ramirez de Molina, A.; Rodriguez-Gonzalez, A.; Gutierrez, R.; Martinez-Pineiro, L.; Sanchez, J.; Bonilla, F.; Rosell, R.; Lacal, J. C. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 2002, 296, 580-583.
8. Eliyahu, G.; Kreizman, T.; Degani, H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer 2007, 120, 1721-1730.
9. Nakagami, K.; Uchida, T.; Ohwada, S.; Koibuchi, Y.; Suda, Y.; Sekine, T.; Morishita, Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res. 1999, 90, 419-424.
10. Ramirez de Molina, A.; Gutierrez, R.; Ramos, M. A.; Silva, J. M.; Silva, J.; Bonilla, F.; Sanchez, J. J.; Lacal, J. C. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002, 21, 4317-4322.
11. Ramirez de Molina, A.; Sarmentero-Estrada, J.; Belda-Iniesta, C.; Taron, M.; Ramirez de Molina, V.; Cejas, P.; Skrzypski, M.; Gallego-Ortega, D.; de Castro, J.; Casado, E.; Garcia-Cabezas, M. A.; Sanchez, J. J.; Nistal, M.; Rosell, R.; Gonzalez-Baron, M.; Lacal, J. C. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007, 8, 889-897.
12. Al-Saeedi, F.; Smith, T.; Welch, A. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay. Anticancer Res. 2007, 27, 901-906.
13. Ramirez de Molina, A.; Gallego-Ortega, D.; Sarmentero, J.; Banez-Coronel, M.; Martin-Cantalejo, Y.; Lacal, J. C. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005, 65, 5647-5653.
14. Mori, N.; Glunde, K.; Takagi, T.; Raman, V.; Bhujwalla, Z. M. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007, 67, 11284-11290.
15. Hernandez-Alcoceba, R.; Fernandez, F.; Lacal, J. C. In vivo anti-tumor activity of choline kinase inhibitors: a novel target for anti-cancer drug discovery. Cancer Res. 1999, 59, 3112-3118.
16. Rodriguez-Gonzalez, A.; Ramirez de Molina, A.; Banez-Coronel, M.; Megias, D.; Lacal, J. C. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int. J. Oncol. 2005, 26, 999-1008.
17. Semizarov, D.; Frost, L.; Sarthy, A.; Kroeger, P.; Halbert, D. N.; Fesik, S. W. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA 2003, 100, 6347-6352.
18. Jackson, A. L.; Bartz, S. R.; Schelter, J.; Kobayashi, S. V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P. S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21, 635-637.
19. Chi, J. T.; Chang, H. Y.; Wang, N. N.; Chang, D. S.; Dunphy, N.; Brown, P. O. Genomewide view of gene silencing by small interfering RNAs. Proc. Natl. Acad. Sci. USA 2003, 100, 6343-6346.
20. Gallego-Ortega, D.; Ramirez De Molina, A.; Gutierrez, R.; Ramos, M. A.; Sarmentero, J.; Cejas, P.; Nistal, M.; Gonzalez Baron, M.; Lacal, J. C. Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int. J. Oncol. 2006, 29, 335-340.
21. Brummelkamp, T. R.; Bernards, R.; Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296, 550-553.
22. Wang, L.; Miura, M.; Bergeron, L.; Zhu, H.; Yuan, J. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994, 78, 739-750.
23. Lazebnik, Y. A.; Kaufmann, S. H.; Desnoyers, S.; Poirier, G. G.; Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371, 346-347.
24. Kaufmann, S. H.; Desnoyers, S.; Ottaviano, Y.; Davidson, N. E.; Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993, 53, 3976-3985.
25. Yamamoto, A.; Hen, R.;Dauer, W. T. The ons and offs of inducible transgenic technology: a review. Neurobiol. Dis. 2001, 8, 923-932.
26. Gossen, M.; Freundlieb, S.; Bender, G.; Muller, G.; Hillen, W.; Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268, 1766-1769.
27. Corbel, S. Y.; Rossi, F. M. Latest developments and in vivo use of the Tet system: ex vivo and in vivo delivery of tetracycline-regulated genes. Curr. Opin. Biotechnol. 2002, 13, 448-452.
28. Blau, H. M.; Rossi, F. M. Tet B or not tet B: advances in tetracycline-inducible gene expression. Proc. Natl. Acad. Sci. USA 1999, 96, 797-799.
29. Berens, C.; Hillen, W. Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur. J. Biochem. 2003, 270, 3109-3121.
30. Rodriguez-Gonzalez, A.; Ramirez de Molina, A.; Fernandez, F.; Ramos, M. A.; Nunez M del, C.; Campos, J.; Lacal, J. C. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003, 22, 8803-8812.
31. Lacal, J. C. Choline kinase: a novel target for antitumor drugs. IDrugs 2001, 4, 419-426.
32. Glunde, K.; Raman, V.; Mori, N.; Bhujwalla, Z. M. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005, 65, 11034-11043.
33. Akahani, S.; Nangia-Makker, P.; Inohara, H.; Kim, H. R.; Raz, A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997, 57, 5272-5276.
34. Yang, R. Y.; Liu, F. T. Galectins in cell growth and apoptosis. Cell. Mol. Life Sci. 2003, 60, 267-276.
35. Song, Y. K.; Billiar, T. R.; Lee, Y. J. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am. J. Pathol. 2002, 160, 1069-1075.
36. Kim, H. R.; Lin, H. M.; Biliran, H.; Raz, A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999, 59, 4148-4154.
37. Choi, J. H.; Chun, K. H.; Raz, A.; Lotan, R. Inhibition of N-(4-hydroxyphenyl)retinamide-induced apoptosis in breast cancer cells by galectin-3. Cancer Biol. Ther. 2004, 3, 447-452.
38. Sommers, C. L.; Byers, S. W.; Thompson, E. W.; Torri, J. A.; Gelmann, E. P. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res. Treat. 1994, 31, 325-335.
39. Seshadri, R.; Raymond, W. A.; Leong, A. S.; Horsfall, D. J.; McCaul, K. Vimentin expression is not associated with poor prognosis in breast cancer. Int. J. Cancer 1996, 67, 353-356.